I Gathmann
Overview
Explore the profile of I Gathmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochhaus A, OBrien S, Guilhot F, Druker B, Branford S, Foroni L, et al.
Leukemia
. 2009 Mar;
23(6):1054-61.
PMID: 19282833
Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571...
2.
Capdeville R, Krahnke T, Hatfield A, Ford J, Van Hoomissen I, Gathmann I
Ann Oncol
. 2008 Mar;
19(7):1320-1326.
PMID: 18344535
Background: Imatinib is a selective inhibitor of the BCR/ABL tyrosine kinase. The remarkable initial results of the first phase I clinical trial published in 1999 prompted the rapid initiation of...
3.
Schmidli H, Peng B, Riviere G, Capdeville R, Hensley M, Gathmann I, et al.
Br J Clin Pharmacol
. 2005 Jun;
60(1):35-44.
PMID: 15963092
Aims: This study was designed to investigate the biochemical and physiological covariates or comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia (CP CML)....
4.
Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al.
Leukemia
. 2003 Oct;
17(12):2401-9.
PMID: 14523461
We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC)....
5.
Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, et al.
Am J Trop Med Hyg
. 2001 Jul;
64(5-6):247-56.
PMID: 11463111
The efficacy-safety and pharmacokinetics of the six-dose regimen of artemether-lumefantrine (Coartem/Riamet; Novartis Pharma AG, Basel, Switzerland) were assessed in a randomized trial in 219 patients (> or = 12 years...
6.
van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, et al.
Trans R Soc Trop Med Hyg
. 2001 Jan;
94(5):545-8.
PMID: 11132386
The efficacy and safety of the 6-dose regimen of artemether-lumefantrine were assessed in an open randomized trial in children and adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand...
7.
Bakshi R, Gathmann I, Alteri E
Trans R Soc Trop Med Hyg
. 2000 Dec;
94(4):419-24.
PMID: 11127248
Artemether-lumefantrine (A-L), a new fixed-dose oral antimalarial drug, combines the fast onset of action of artemether (an artemisinin derivative) in terms of parasite clearance with the high cure rate of...
8.
Kshirsagar N, Gogtay N, Moorthy N, Garg M, Dalvi S, Chogle A, et al.
Am J Trop Med Hyg
. 2000 Oct;
62(3):402-8.
PMID: 11037786
In India, treatment of acute, uncomplicated Plasmodium falciparum malaria is becoming increasingly difficult due to resistance to chloroquine, thus there is a need for new antimalarial drugs. CGP 56697 (co-artemether),...
9.
van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, et al.
Am J Trop Med Hyg
. 2000 Feb;
61(6):964-7.
PMID: 10674679
Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was...
10.
van Agtmael M, Bouchaud O, Malvy D, Delmont J, Danis M, Barette S, et al.
Int J Antimicrob Agents
. 1999 Jul;
12(2):159-69.
PMID: 10418762
CGP 56697 (Riamet) is a new oral anti-malarial drug composed of artemether and lumefantrine (benflumetol) which combines the fast, short-acting artemether for rapid parasite clearance with the prolonged action of...